Fact Sheet 2 - Transitional Cycles

Please note: The information on this page is no longer current and is only included here for historical reference.

Current information is maintained on the Price Disclosure (SPD) page.

 

PDF printable version of this page (PDF 330KB)

Expanded and Accelerated Price Disclosure (EAPD) commences on 1 December 2010. On that date, three of the data collection cycles under the price disclosure program prior to 1 December 2010, will be in progress (still in the data collection phase of the cycle). These cycles will become known as the Transitional Cycles.

The table below outlines the current collection period for each of these cycles and the Transitional Cycle they will become:

Current Collection Period Transitional Cycle
1 January – 31 December 1
1 May – 30 April 2
1 September – 31 August 3

This Fact Sheet will help you understand how these drugs will transition into the new processes and provisions of EAPD, including:

  • which drugs will be in each Transitional Cycle;
  • the timeframes for each Transitional Cycle; and
  • how each Transitional Cycle merges into the Main Disclosure Cycle.

Transitional Cycle 1

Drugs in Transitional Cycle 1

The following Drugs currently disclosing for the data collection period 1 January to 31 December will form part of Transitional Cycle 1.

Drug Manner of Administration
Alendronic acid Oral
Ceftriaxone Injection
Cisplatin Injection
Fluconazole Oral
Fluconazole Injection
Fludarabine Injection
Levodopa with Carbidopa Oral
Naltrexone Oral
Risperidone Oral
Topiramate Oral
Vancomycin Injection

Timeframes for Transitional Cycle 1

The table below outlines the revised data collection and reporting periods for Transitional Cycle 1.

Current Collection Period Transitional Cycle Data Collection Start & End Reporting Periods1 (Excluding completed Reporting periods2) Submission Deadlines3 Reduction Date Note this remains unchanged Data collection flows into Main Cycle
1 January – 31 December 1 January 2010 –
30 September 2011

(21 months data collection)
1 October 2010 –
31 March 2011
12 May 2011 1 April 2012 1 October 2011
1 April 2011 –
30 September 2011
11 November 2011

1 Including incentive data.
2 Under the price disclosure policy (prior to 1 December 2010), these drugs have completed reporting for the period of 1 January 2010 to 30 September 2010.
3 Noting that data submitted quarterly before 01/12/10 will still be included into WADP calculations for these transitional cycles.

How Transitional Cycle 1 merges into Main Disclosure Cycle

Once a brand has completed the data collection period for Transitional Cycle 1 it will merge into the next available Main Disclosure Cycle, commencing on 1 October 2011, with no gap in the data collection periods (as shown in the diagram below).

EAPD Transitional Cycle 1 process

 

Transitional Cycle 2

Drugs in Transitional Cycle 2

The following Drugs currently disclosing for the data collection period 1 May to 30 April will form part of Transitional Cycle 2.

Drug Manner of Administration
Carvedilol Oral
Clopidogrel Oral
Enalapril with hydrochlorothiazide Oral
Gemcitabine Injection
Irinotecan Injection
Memantine Oral
Paclitaxel Injection
Sumatriptan Oral
Vinorelbine Injection

Timeframes for Transitional Cycle 2

The table below outlines the revised data collection and reporting periods for Transitional Cycle 2.

Current Collection Period Transitional Cycle Data Collection Start & End Reporting Periods1 (Excluding completed Reporting periods2) Submission Deadlines3 Reduction Date Note this remains unchanged Data collection fl ows into Main Cycle
1 May –
30 April
1 May 2010 –
30 September 2011

(17 months data collection)
1 November 2010 –
31 March 2011
12 May 2011 1 April 2012 1 October 2011
1 April 2011 –
30 September 2011
11 November 2011

1 Including incentive data.
2 Under the price disclosure policy (prior to 1 December 2010), these drugs have completed reporting for the period of 1 May 2010 to 31 October 2010.
3 Noting that data submitted quarterly before 01/12/10 will still be included into WADP calculations for these transitional cycles.

How Transitional Cycle 2 merges into Main Disclosure Cycle

Once a brand has completed the data collection period for Transitional Cycle 2 it will merge into the next available Main Disclosure Cycle, commencing on 1 October 2011, with no gap in the data collection periods (as shown in the diagram below).

EAPD Transitional Cycle 2 process

Transitional Cycle 3

Drugs in Transitional Cycle 3

The following Drugs currently disclosing for the data collection period 1 September to 31 August will form part of Transitional Cycle 3.

Drug Manner of Administration
Alendronic acid with colecalciferol Oral
Amisulpride Oral
Azithromycin Oral
Bicalutamide Oral
Bisoprolol Oral
Cabergoline Oral
Cefalotin Injection
Doxorubicin Injection/Intravesical
Escitalopram Oral
Famciclovir Oral
Fosinopril with hydrochlorothiazide Oral
Glucose Injection
Levetiracetam Oral
Meloxicam Oral
Mitozantrone Injection
Morphine Oral
Ondansetron Injection
Ondansetron Oral
Oxaliplatin Injection
Oxazepam Oral
Oxybutynin Oral
Perindopril with indapamide Oral
Prochlorperazine Oral
Sodium Chloride Injection
Sodium Lactate Compound Injection
Valproic acid Oral

Timeframes for Transitional Cycle 3

The table below outlines the revised data collection and reporting periods for Transitional Cycle 3.

Current
Collection
Period
Transitional Cycle
Data Collection
Start & End
Reporting Periods7 Submission
Deadlines8
Reduction Date
Note this remains
unchanged
Data collection
flows into Main
Cycle
1 September –
31 August
1 September 2010 –
31 January 2012

(13 months data
collection)
1 September 2010 –
31 March 2011
12 May 2011 1 August 2012 1 February 2012
1 April 2011 –
30 September 2011
11 November 2011
1 October 2011 –
31 January 2012
13 March 2012

7 Including incentive data.
8 Noting that data submitted quarterly before 01/12/10 will still be included into WADP calculations for these transitional cycles.

How Transitional Cycle 3 merges into Main Disclosure Cycle

Once a brand has completed the data collection period for Transitional Cycle 3 it will merge into the next available Main Disclosure Cycle, commencing on 1 October 2012, with no gap in the data collection periods (as shown in the diagram below).

How Transitional Cycle 3 merges into Main Disclosure Cycle

EAPD Transitional Cycle 3 process

EAPD Transitional Cycle 3 process

 

 

 

Novemeber 2012